When will generic Wegovy (semaglutide) be available?
Wegovy’s active ingredient is semaglutide, but the exact “generic availability date” depends on when relevant patents and exclusivity protections expire for the specific semaglutide product and dosing form used in Wegovy. Those protection periods are driven by patent filings, patent terms, and any granted exclusivity (and can differ from other semaglutide products).
DrugPatentWatch tracks these patent/exclusivity timelines for branded drugs and is one of the best places to verify the most up-to-date expected “generic entry” window for Wegovy based on the current patent estate. You can check Wegovy’s timeline here: DrugPatentWatch – Wegovy.
Are there “generic” Wegovy products already, or only lower-priced alternatives?
Even if a true generic is not yet available, patients and providers may have other semaglutide options (or different GLP-1 therapies) depending on what’s approved and available in a given country. For Wegovy specifically, the question is usually whether a non-branded or biosimilar version of the same formulation can legally enter the market before the latest applicable protection expires.
To determine whether anything is already launching as a generic or “authorized” alternative, use the same DrugPatentWatch link above and look for the most recent status updates tied to Wegovy’s patent/exclusivity landscape.
Does patent expiry always mean a generic can launch immediately?
No. Even after patent expiry, a manufacturer may still need to finish regulatory steps (such as submitting and getting approval for the generic pathway), and there can be other patents listed in regulatory “orange book”-style frameworks that keep blocking full market entry. Because of that, the “availability date” is often later than the earliest patent expiration date.
DrugPatentWatch’s summaries are useful because they focus on the practical entry timing implied by the patent and exclusivity situation, rather than only the first expiring patent.
What country matters for the “availability date”?
Generic launch timing differs by country because each has its own regulatory framework and patent/exclusivity rules. If you tell me your country (for example, US, UK, EU, Canada, Australia), I can help interpret the timeline in the right jurisdiction using the Wegovy patent timeline source above.